VIGEO THERAPEUTICS
Vigeo Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutic agents intended to treat an advanced malignant tumor that can effectively treat multiple types of cancer and improve the lives of patients. The company building a first-in-class drug discovery pipeline that reprograms the tumor immune microenvironment (TIME). They plan to commence multiple combination studies to evaluate VT1021 in combination with chemotherapies and/or anti-PD-1 antibodies. The company was established in 2011 and is headquartered in Cambridge, Massachusetts.
VIGEO THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2011-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.vigeotherapeutics.com
Total Employee:
11+
Status:
Active
Contact:
617-945-0385
Total Funding:
10 M USD
Technology used in webpage:
Euro SPF Microsoft Exchange Online Office 365 Mail GoDaddy DNS GoDaddy
Similar Organizations
Aegerion Pharmaceuticals
Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Biodel
Biodel is a biopharmaceutical company developing and commercializing therapeutics for the treatment of diabetes.
Cascadian Therapeutics
Cascadian Therapeutics is a bio-pharmaceutical company that researches, develops, and sells therapeutic products for treatment of cancer.
Cornerstone Therapeutics
Cornerstone Therapeutics is a pharmaceutical company focused on developing and commercializing products for the respiratory system.
Microbion
Microbion is a pharmaceutical company developing therapeutics for the treatment of bacterial infections.
Milestone Pharmaceuticals
Milestone Pharmaceuticals is a drug development company developing small molecule therapeutics for the treatment of cardiovascular diseases.
Progenics Pharmaceuticals
Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.
Current Advisors List
Board_member
Current Employees Featured
Daniel Geffken Interim Chief Financial Officer @ Vigeo Therapeutics
Interim Chief Financial Officer
2017-11-01
Randy Watnick Co-Founder @ Vigeo Therapeutics
Co-Founder
Jim Mahoney Chief Executive Officer @ Vigeo Therapeutics
Chief Executive Officer
2021-02-01
Peter B. Finn Director @ Vigeo Therapeutics
Director
Founder
Investors List
Morningside Venture Investments
Morningside Venture Investments investment in Series A - Vigeo Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-09-21 | Vigeo Therapeutics Provides Clinical Update for Lead Asset VT1021 and Welcomes New Chief Executive Officer |
Official Site Inspections
http://www.vigeotherapeutics.com Semrush global rank: 13.19 M Semrush visits lastest month: 78
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Vigeo Therapeutics"
Home - Vigeo
Mar 26, 2024 · We are building a first-in-class drug development pipeline aimed at reinvigorating the immune system to combat cancer and inflammatory diseases. Vigeo is currently …See details»
Overview - Vigeo
Vigeo Therapeutics, based in Cambridge, MA, is a clinical-stage biopharmaceutical company developing novel therapeutics that have the potential to treat multiple types of cancer and improve the lives of patients.See details»
Vigeo Therapeutics - Crunchbase Company Profile
Vigeo Therapeutics is a biopharmaceutical company developing novel therapeutic agents intended to treat advanced malignant tumors. View contacts for Vigeo Therapeutics to access new leads and connect with decision-makers.See details»
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 …
Jan 20, 2022 · Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug …See details»
Vigeo Therapeutics - LinkedIn
Vigeo Therapeutics is a clinical stage company developing novel therapeutic agents for the treatment of cancer. Over 25 years experience growing companies and commercializing new technologies....See details»
Vigeo Therapeutics - PitchBook
Information on valuation, funding, cap tables, investors, and executives for Vigeo Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Vigeo Therapeutics - Overview, News & Similar companies
Jun 2, 2023 · Vigeo Therapeutics contact info: Phone number: (617) 340-6073 Website: www.vigeotherapeutics.com What does Vigeo Therapeutics do? Based in Cambridge, MA, …See details»
Vigeo Therapeutics Advances VT1021 Into Phase 2-3 …
Jan 20, 2022 · VT1021 will be part of GCAR's GBM AGILE Phase 2-3 adaptive platform trial for patients with glioblastoma. VT1021 is a first-in-class compound that, by binding to MDSCs, …See details»
Head, Clinical Operations at Vigeo Therapeutics - The Org
Harold Pestana is the current head of Clinical Operations at Vigeo Therapeutics. Prior to this, they served as Director of Clinical Operations at Radius Health, Inc. from May 2018 to May 2021. …See details»
Working At Vigeo Therapeutics: Company Overview and Culture
Vigeotherapeutics.com. Organization Type. Private. Social Media. Vigeo Therapeutics, Inc. operates in the healthcare industry focusing on biotechnology business. Based in Cambridge, …See details»
Vigeo Therapeutics Provides Clinical Update for Lead Asset …
CAMBRIDGE, Mass., Sept. 21, 2021 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced completion …See details»
Overview - Vigeo
Oct 1, 2023 · Vigeo is the first, and only, company developing therapies designed to stimulate Tsp-1 expression by replicating the biological activity of prosaposin (PSAP).See details»
Vigeo Therapeutics Announces New Phase 1/2 Data from its …
CAMBRIDGE, Mass., Nov. 16, 2021 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical …See details»
Vigeo Therapeutics Announces New Phase 1/2 Data from its …
Cambridge MA – November 9, 2021 (PR Newswire) – Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical …See details»
Vigeo Therapeutics Provides Clinical Update for Lead Asset
CAMBRIDGE, Mass., Sept. 21, 2021 /PRNewswire/ -- Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced completion …See details»
Vigeo Therapeutics Doses First Patients in Expansion Phase of its …
Apr 9, 2020 · Vigeo is developing therapies that target the TIME via induction of thrombospondin-1 (Tsp-1). Tsp-1 is a naturally occurring, potent anti-tumorigenic protein with a pleiotropic …See details»
Vigeo Therapeutics Provides Clinical Update for Lead Asset …
Sep 21, 2021 · Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug …See details»
Vigeo Therapeutics to Present New Phase 1/2 VT1021 Dose …
Nov 9, 2020 · Based in Cambridge, MA, Vigeo Therapeutics is a clinical-stage immuno-oncology company pioneering novel cancer therapies. The company is building a first-in-class drug …See details»
Vigeo Therapeutics Announces New Phase 1/2 Data from its …
Cambridge MA – November 16, 2021 (PR Newswire) – Vigeo Therapeutics, a clinical-stage immuno-oncology company pioneering novel cancer therapies, today announced new clinical …See details»